オプションチェーンは、Verastemの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Verastemの市場センチメントを評価します。.

Verastem (NASDAQ:VSTM) 株価情報, オプションチェーン

Verastem

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Verastem Inc

<h3>Gainers</h3>
<ul>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares rose 252.0% to $4.77 during Tuesday's pre-market session. The company's market cap stands at $26.0 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 147.13% to $1.08. The company's market cap stands at $8.9 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock rose 99.2% to $0.23. The company's market cap stands at $25.1 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares moved upwards by 39.99% to $1.47. The market value of their outstanding shares is at $52.5 million. </li>
<li>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares moved upwards by 33.51% to $4.9. The company's market cap stands at $218.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock rose 26.19% to $0.56. The market value of their outstanding shares is at $2.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares decreased by 53.4% to $1.09 during Tuesday's pre-market session. The market value of their outstanding shares is at $227.4 million. </li>
<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) shares declined by 33.54% to $2.16. The market value of their outstanding shares is at $21.9 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) stock decreased by 18.56% to $0.61. The company's market cap stands at $63.3 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 18.21% to $0.37. The market value of their outstanding shares is at $3.0 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 10.65% to $1.93. The market value of their outstanding shares is at $8.0 million. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) stock fell 9.03% to $5.95. The company's market cap stands at $196.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BDMD

COCP

EYEN

LXEO

ONCO

PLRZ

SGMO

SXTC

TLSA

VRPX

VSTM

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

On Monday, the FDA accepted for review the New Drug Application under the accelerated approval pathway for Verastem Oncology&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) <a href="https://www.benzinga.com/pressreleases/24/12/b42733460/verastem-oncology-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-avutome" target="_blank" rel="noreferrer noopener">avutometinib</a>.
The company seeks approval of avutometinib in combination with defactinib for adult patients with recurrent low-grade serous ovarian cancer (LGSOC) who received at least one prior systemic therapy and have a KRAS mutation.
The NDA, which was completed in October 2024, has been granted Priority Review with a Prescription Drug User Fee Act action date of June 30, 2025.
In addition, the FDA has stated that it is not currently planning to hold an advisory committee meeting to discuss the application.
The filing was based on a primary Phase 2 RAMP 201 clinical trial analysis.
The <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.verastem.com%2Fnews-releases%2Fnews-release-details%2Fverastem-oncology-presents-positive-updated-ramp-201-data&amp;esheet=54171616&amp;newsitemid=20241230294719&amp;lan=en-US&amp;anchor=results&amp;index=1&amp;md5=a67a2129bd99232dbc3b31eb12f7bb27" target="_blank" rel="noreferrer noopener">results</a> were presented in an oral presentation at the International Gynecologic Cancer Society Annual Global Meeting in October 2024 and demonstrated that the combination of avutometinib plus defactinib resulted in a substantial overall response rate confirmed by a blinded independent central review, with responses that were typically durable, and that the combination was generally well-tolerated in patients with recurrent KRAS mutant LGSOC.
The NDA also includes supportive data from the FRAME Phase 1 trial, the first study conducted with the combination therapy in recurrent LGSOC.
The company is currently enrolling patients with recurrent LGSOC regardless of KRAS mutation status for RAMP 301, an international Phase 3 trial.
The trial will serve as a confirmatory study for the initial indication and has the potential to support an expanded indication regardless of KRAS mutation status.
In May, Verastem Oncology revealed initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel as a first-line treatment for patients with <a href="https://www.benzinga.com/general/biotech/24/05/39006618/whats-going-on-with-mid-cap-cancer-focused-verastem-oncology-stock-on-friday" target="_blank" rel="noreferrer noopener">metastatic pancreatic cancer</a>. 
Price Action: VSTM stock is up 26.4% at $4.64 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42740171/comstock-expands-global-reach-with-renewable-fuel-deal-in-pakistan" target="_blank" rel="noreferrer noopener">Comstock Expands Global Reach With Renewable Fuel Deal In Pakistan: Details</a></li>
</ul>
Photo: Shutterstock

Biotech

News

Health Care

Trading Ideas

General

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

If approved, avutometinib in combination with defactinib would be the first-ever FDA-approved treatment specifically for adults with recurrent KRAS mutant LGSOC, the company said.
 &nbsp;

Verastem Oncology Says FDA Accepted For Review The NDA Under Accelerated Approval Pathway For Avutometinib In Combination With Defactinib; PDUFA Target Action Date Is June 30, 2025

Mizuho analyst Mara Goldstein maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Outperform and raises the price target from $7 to $9.

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Verastem, Raises Price Target to $9

HC Wainwright &amp; Co. analyst Sean Lee reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and maintains $7 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $7 Price Target

No dose-limiting toxicities were observed in the RAMP 203 first triplet combination cohort of avutometinib and LUMAKRAS&#x2122; (sotorasib) plus defactinib in patients previously treated with a G12C inhibitor

Verastem Reports RAMP 203 Data: No Dose-Limiting Toxicities In Triplet Therapy For KRAS G12C NSCLC

Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.74) by 18.92 percent. This is a 23.94 percent decrease over losses of $(0.71) per share from the same period last year.

Earnings

Earnings Misses

Verastem Q3 Adj $(0.88) Misses $(0.74) Estimate

Recurrent low-grade serous ovarian cancer is a rare cancer with no FDA-approved treatments
Company seeking accelerated approval and priority review of its NDA submission in patients with KRAS mutant low-grade serous ovarian cancer; FDA filing decision expected before the end of 2024 with potential for FDA approval decision by mid-2025
Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has completed its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational and potential first-in-class combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral selective FAK inhibitor, for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC), who received at least one prior systemic therapy.
There are currently no FDA-approved treatments specifically for LGSOC, a rare and distinct ovarian cancer that differs from high-grade serous ovarian cancer in both its biology and behavior. Verastem submitted the NDA under the FDA's Accelerated Approval pathway and requested a Priority Review based on the combination's potential to address significant unmet medical need among patients with recurrent LGSOC. If granted, the FDA review will be completed within six months following the 60-day filing period. If approved, Verastem expects that avutometinib plus defactinib will be the first-ever FDA-approved treatment specifically for adult patients in the United States with recurrent KRAS mutant LGSOC.

Verastem Oncology Completes Rolling NDA Submission To The FDA For Avutometinib Plus Defactinib As A Treatment For Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer; Seeking Accelerated Approval And Priority Review Of Its NDA Submission In Patients With KRAS Mutant Low-Grade Serous Ovarian Cancer; FDA Filing Decision Expected Before The End Of 2024 With Potential For FDA Approval Decision By Mid-2025

RBC Capital analyst Gregory Renza reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Outperform and maintains $13 price target.

RBC Capital Reiterates Outperform on Verastem, Maintains $13 Price Target

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Verastem

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares increased by 109.6% to $2.18 during Thursday's regular session. The company's market cap stands at $371.9 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock increased by 61.42% to $0.52. The market value of their outstanding shares is at $3.4 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock increased by 37.97% to $0.46. The company's market cap stands at $13.7 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) stock rose 36.93% to $1.14. The company's market cap stands at $19.3 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock increased by 27.16% to $6.46. The company's market cap stands at $33.6 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock increased by 25.11% to $0.46. The market value of their outstanding shares is at $74.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock declined by 33.9% to $5.55 during Thursday's regular session. The market value of their outstanding shares is at $80.5 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock declined by 31.23% to $4.45. The company's market cap stands at $4.5 million. </li>
<li>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) stock fell 19.67% to $2.67. The market value of their outstanding shares is at $107.6 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares declined by 18.24% to $1.47. The market value of their outstanding shares is at $272.7 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock fell 15.52% to $0.79. The company's market cap stands at $123.2 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares decreased by 14.99% to $0.67. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

BDRX

CERS

KZIA

MTEM

PIII

QNRX

RENB

SONN

TLPH

TVGN

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

Verastem shares are trading lower. The company presented updated data on the Avutometinib And Defactinib combo in recurrent low-grade serous ovarian cancer at IGCS 2024.

<ul>
<li>Robust overall response rates observed (31%&nbsp;overall,&nbsp;44%&nbsp;in KRAS mutant,&nbsp;17%&nbsp;in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumab</li>
<li>Patients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months); 22 months in KRAS mutant population</li>
<li>The Company recently met with the FDA to review the mature data set and remains on track to complete the NDA submission in October 2024</li>
<li>Additional data to be presented at the IGCS meeting and during Company-hosted investor conference call and webcast today, October 17, 2024 at 4:30 pm EDT</li>
</ul>

Verastem Oncology Presents Updated Data On Avutometinib And Defactinib Combo In Recurrent Low-Grade Serous Ovarian Cancer At IGCS 2024

Verastem Oncology Announced Further Details For Its Late-breaking Presentation Of Mature Data From The Ongoing Phase 2 Ramp 201 Clinical Trial To Be Presented As An Oral Presentation At A Plenary Session At The International Gynecologic Cancer Society

Verastem shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a $13 price target.

Guggenheim analyst Michael Schmidt initiates coverage on Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy rating and announces Price Target of $13.

Initiation

Guggenheim Initiates Coverage On Verastem with Buy Rating, Announces Price Target of $13

Verastem Oncology To Present Late-breaking Abstract Of The Mature Data From The Ongoing Phase 2 RAMP 201 Clinical Trial At IGCS Annual Meeting

Truist Securities analyst Srikripa Devarakonda maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and lowers the price target from $18 to $15.

Truist Securities Maintains Buy on Verastem, Lowers Price Target to $15

HC Wainwright &amp; Co. analyst Sean Lee maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and lowers the price target from $17.5 to $7.

HC Wainwright & Co. Maintains Buy on Verastem, Lowers Price Target to $7

FDA accepts Verastem NDA for priority review, stock jumps 20% (update)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 12/31/2024, According to Top Analysts

Biggest stock movers Tuesday: VSTM, ACAD

BTIG raised the firm's price target on Verastem (VSTM) to $20 from $13 and keeps a Buy rating on the shares after the company announced the FDA acc...

Verastem price target raised to $20 from $13 at BTIG

Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER – Verastem (VSTM) up 29% after announcing that the FDA has...

Morning Movers: EHang jumps following guidance raise

Biggest stock movers Tuesday: VSTM, DAVE, SGMO and more

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Verastem: BLA Acceptance Puts Key Goals In Sight

Verastem: Planning The PDUFA Run-Up

Momentum reigned in 2024: Buy-rated U.S. stocks with the highest RSI

ACAD

AENT

AOUT

AXSM

CDTX

CHEF

CHNR

CSBR

DAVE

DXPE

EHTH

GEVO

LPTH

MAIN

MIND

MIST

MRNS

NUVL

PBAM

PGEN

PSTX

PTVE

RCKT

RGTI

SKIL

SPMO

URBN

XMTR

Press Releases

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Verastem Oncology to Participate in Upcoming Investor Conferences

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Management

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Comments

Verastem

Verastem (VSTM) オプション

Verastem (NASDAQ:VSTM) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル